NCT06332430View on ClinicalTrials.gov

Intratumoral CAN2109 in Subjects With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2026

Conditions
Solid TumorLymphoma
Interventions
DRUG

CAN2109

CAN2109 IT injection (once every 3 weeks)

Trial Locations (1)

510535

RECRUITING

Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou

Sponsors
All Listed Sponsors
lead

Canwell Biotech Limited

INDUSTRY

NCT06332430 - Intratumoral CAN2109 in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter